AU Patent

AU2019286326A1 — Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Assigned to Poxel SA · Expires 2020-12-10 · 5y expired

What this patent protects

This invention pertains to a film-coated tablet comprising an inner core and an external coating, wherein the inner core comprises a high proportion of a specific triazine derivative, namely 2- amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine and pharmaceutically accepta…

USPTO Abstract

This invention pertains to a film-coated tablet comprising an inner core and an external coating, wherein the inner core comprises a high proportion of a specific triazine derivative, namely 2- amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine and pharmaceutically acceptable salts thereof, and a specific binder. It is also directed to the use of these tablets in the treatment of diabetes and/or complications thereof. This invention is further directed to a specific process for the manufacture of these film-coated tablets, which involves a granulation step in a high- shear mixer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019286326A1
Jurisdiction
AU
Classification
—
Expires
2020-12-10
Drug substance claim
No
Drug product claim
No
Assignee
Poxel SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.